CA3211403A1 - Anti-cldn18.2 antibody conjugates - Google Patents
Anti-cldn18.2 antibody conjugates Download PDFInfo
- Publication number
- CA3211403A1 CA3211403A1 CA3211403A CA3211403A CA3211403A1 CA 3211403 A1 CA3211403 A1 CA 3211403A1 CA 3211403 A CA3211403 A CA 3211403A CA 3211403 A CA3211403 A CA 3211403A CA 3211403 A1 CA3211403 A1 CA 3211403A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- sequence
- antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/076910 | 2021-02-19 | ||
| CN2021076910 | 2021-02-19 | ||
| CN2022074750 | 2022-01-28 | ||
| CNPCT/CN2022/074750 | 2022-01-28 | ||
| PCT/CN2022/076810 WO2022174809A1 (en) | 2021-02-19 | 2022-02-18 | Anti-cldn18.2 antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3211403A1 true CA3211403A1 (en) | 2022-08-25 |
Family
ID=82932096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3211403A Pending CA3211403A1 (en) | 2021-02-19 | 2022-02-18 | Anti-cldn18.2 antibody conjugates |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240307564A1 (https=) |
| EP (1) | EP4294441A4 (https=) |
| JP (1) | JP2024511281A (https=) |
| KR (1) | KR20230146623A (https=) |
| CN (1) | CN117460528A (https=) |
| AU (1) | AU2022223150A1 (https=) |
| CA (1) | CA3211403A1 (https=) |
| TW (1) | TW202302153A (https=) |
| WO (1) | WO2022174809A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024041574A1 (en) * | 2022-08-24 | 2024-02-29 | Suzhou Transcenta Therapeutics Co., Ltd. | Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates |
| KR20240176948A (ko) * | 2023-06-15 | 2024-12-26 | 에이비온 주식회사 | 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도 |
| KR20250062080A (ko) | 2023-10-30 | 2025-05-08 | 주식회사 엘지에너지솔루션 | 배터리 데이터 수집 서버 및 이의 동작 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP2852409B1 (en) * | 2012-05-23 | 2020-03-25 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP3765522A4 (en) * | 2018-03-14 | 2022-05-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODIES |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| WO2020025792A1 (en) * | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN114206935B (zh) * | 2019-05-24 | 2024-01-12 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| JP7767270B2 (ja) * | 2019-08-20 | 2025-11-11 | スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド | 新規抗ｃｌｄｎ１８．２抗体 |
| CN111777681B (zh) * | 2020-07-06 | 2022-10-11 | 康诺亚生物医药科技（成都）有限公司 | 一种结合紧密连接蛋白-18.2的抗体及其用途 |
-
2022
- 2022-02-18 US US18/546,980 patent/US20240307564A1/en active Pending
- 2022-02-18 JP JP2023550307A patent/JP2024511281A/ja active Pending
- 2022-02-18 KR KR1020237031810A patent/KR20230146623A/ko active Pending
- 2022-02-18 EP EP22755582.8A patent/EP4294441A4/en active Pending
- 2022-02-18 CA CA3211403A patent/CA3211403A1/en active Pending
- 2022-02-18 WO PCT/CN2022/076810 patent/WO2022174809A1/en not_active Ceased
- 2022-02-18 AU AU2022223150A patent/AU2022223150A1/en active Pending
- 2022-02-18 CN CN202280015857.3A patent/CN117460528A/zh active Pending
- 2022-02-21 TW TW111106264A patent/TW202302153A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117460528A (zh) | 2024-01-26 |
| KR20230146623A (ko) | 2023-10-19 |
| US20240307564A1 (en) | 2024-09-19 |
| AU2022223150A9 (en) | 2024-01-04 |
| WO2022174809A1 (en) | 2022-08-25 |
| TW202302153A (zh) | 2023-01-16 |
| AU2022223150A1 (en) | 2023-09-21 |
| JP2024511281A (ja) | 2024-03-13 |
| EP4294441A1 (en) | 2023-12-27 |
| EP4294441A4 (en) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5919604B2 (ja) | 抗膵癌抗体 | |
| KR101820029B1 (ko) | 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편 | |
| KR20220057517A (ko) | 신생아 fc 수용체에 대한 감소된 친화성을 갖는 psma 결합을 위한 항체 | |
| CN107847584A (zh) | 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途 | |
| US20240342323A1 (en) | Antibodies against caix with reduced affinity for the neonatal fc receptor | |
| WO2022174809A1 (en) | Anti-cldn18.2 antibody conjugates | |
| US20200188541A1 (en) | Radiolabeled biomolecules and their use | |
| US20240307563A1 (en) | Radiolabeled met binding proteins for immuno-pet imaging | |
| WO2024041574A1 (en) | Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates | |
| US20240124595A1 (en) | Antibodies to igf2r and methods | |
| JP2024505963A (ja) | 抗ｏｘＭＩＦ放射性免疫コンジュゲート | |
| HK40106087A (zh) | 抗cldn18.2抗体缀合物 | |
| TW202607033A (zh) | 抗ｒｏｒ２抗體－放射性核種結合物 | |
| WO2025035107A2 (en) | Trophoblast glycoprotein antibody compositions and methods of use | |
| EA052523B1 (ru) | Антитела против cd44v6 и их использование для лечения онкологических заболеваний, характеризующихся гиперэкспрессией cd44v6 | |
| CN119451984A (zh) | 抗cd44v6抗体及其用于治疗cd44v6过表达癌症的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250123 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250123 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250123 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260122 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260217 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260217 |